Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Pacific Palisades, California Clinical Trials

A listing of Pacific Palisades, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (11) clinical trials

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A)

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma …

Phase

2.55 miles

Learn More »

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Open-label, long-term safety study of ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study medication will be applied by the qualifying subjects topically once daily for 24 weeks. Cohort 1 subjects are rollover subjects from the ARQ-154-203 trial. Cohort 2 include …

Phase

2.55 miles

Learn More »

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which …

Phase

2.55 miles

Learn More »

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02B is to evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma …

Phase

3.9 miles

Learn More »

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate to Severe Atopic Dermatitis.

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.

Phase

3.9 miles

Learn More »

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

The main objectives of this trial are to evaluate the efficacy and safety of oral BI 1358894 compared to placebo over a 6-week treatment period in participants with Major Depressive Disorder (MDD) and with inadequate response to antidepressants (SSRI or SNRI) utilizing a decentralized clinical trial (DCT) model.

Phase

7.02 miles

Learn More »

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and tolerability of rotigotine in adolescent subjects with idiopathic RLS.

Phase

7.02 miles

Learn More »

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg administered by subcutaneous injection every other week (as per label guidelines) in adult participants on background topical therapy, …

Phase

7.81 miles

Learn More »

International Registry of Coronavirus (COVID-19) Exposure in Pregnancy

The International Registry of Coronavirus Exposure in Pregnancy (IRCEP) will enroll women 18 years of age and older who are currently pregnant or have been pregnant women within the last 6 months, and who have been tested for SARS-CoV-2 (regardless of the result) or have been clinically diagnosed with COVID-19 …

Phase N/A

9.35 miles

Learn More »

Evaluation of Safety Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

An interventional, double-blind, randomized, intracohort placebo-controlled design will be used to test safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in 36 patients 18 and 70 years of age with documented dcSS. There will up a screening period of up to 28 days, 84 days treatment period, and 28 days …

Phase

9.35 miles

Learn More »